Drug-Receptor Interactions

Drug-receptor interactions describe how a compound binds to a macromolecular target and produces a response. Two properties govern the encounter: affinity, the strength with which the ligand binds, and efficacy, the ability of the bound ligand to change the target's activity. For natural products this framework explains how plant and microbial metabolites act as agonists, antagonists, or modulators, and why some engage several receptors at once.

Definition

A drug-receptor interaction is the reversible (or, less commonly, irreversible) binding of a ligand to a receptor or other molecular target, characterized by its affinity and by the efficacy with which the bound ligand alters the target's function.

Scope

This entry, framed within natural product pharmacology, covers the principles of ligand binding — affinity, efficacy, agonism, antagonism, and modulation — and how natural products fit them, including their tendency toward multi-target engagement. It complements the separate drug-receptor-interactions node maintained under clinical pharmacodynamics. It is conceptual and does not provide dosing or treatment guidance.

Core questions

• What distinguishes affinity from efficacy in a ligand-receptor interaction?
• How do agonists, antagonists, partial agonists, and modulators differ in their effect on a receptor?
• How do natural products engage receptors, enzymes, and other targets?
• Why do many natural products bind more than one target, and what does that imply?

Key concepts

• Affinity and the equilibrium dissociation constant
• Efficacy and intrinsic activity
• Agonism, partial agonism, and inverse agonism
• Competitive and non-competitive antagonism
• Allosteric modulation
• Multi-target engagement (polypharmacology)
• Selectivity and binding specificity

Mechanisms

A ligand first binds its target with a characteristic affinity; whether binding then produces a response depends on efficacy. Full agonists elicit a maximal response, partial agonists a submaximal one, antagonists occupy the site without activating it, and allosteric modulators bind a distinct site to tune the target's activity — concepts systematized in receptor pharmacology (Kenakin, 2012). Natural products engage this same machinery, and because their chemical space is broad, many bind multiple targets, so a network-pharmacology view often describes their action better than a single-receptor model (Hopkins, 2008). The continued yield of receptor-active natural product scaffolds in drug discovery reflects the structural fit between these molecules and biological targets (Newman & Cragg, 2016; Atanasov et al., 2021).

Clinical relevance

Affinity and efficacy underpin how the action and selectivity of natural products are characterized and compared, supporting evidence appraisal and the interpretation of binding and functional assays. This entry explains those principles and is not a basis for individual diagnostic or treatment decisions.

History

The receptor concept and the distinction between affinity and efficacy were developed over the twentieth century as quantitative pharmacology matured, and they remain the foundation of how ligand-target interactions are described (Kenakin, 2012). As target profiling broadened, the recognition that many ligands, natural products among them, engage multiple receptors gave rise to network pharmacology as an explicit framework (Hopkins, 2008).

Key figures

• Terry P. Kenakin
• Andrew L. Hopkins
• David J. Newman
• Atanas G. Atanasov

Seminal works

• kenakin-2012
• hopkins-2008

Frequently asked questions

What is the difference between affinity and efficacy?

Affinity is how tightly a ligand binds its target; efficacy is how effectively the bound ligand changes the target's activity. A molecule can bind strongly yet produce little or no response.

Why do natural products often bind several receptors?

Their broad chemical diversity lets many of them fit more than one target, so their pharmacology is frequently described with a multi-target or network framework rather than a single-receptor model.